NASDAQ:CNAT - Conatus Pharmaceuticals Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00 %
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$2.26
▼ -0.14 (-5.83%)
Get New Conatus Pharmaceuticals Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for CNAT and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for CNAT

Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for Conatus Pharmaceuticals in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $2.26.

This chart shows the closing price for CNAT for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is N/A

The current consensus among 0 investment analysts is to n/a stock in Conatus Pharmaceuticals. This N/A consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/16/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/17/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/15/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/13/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/11/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/12/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/11/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/10/2022

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/3/2019HC WainwrightReiterated RatingHold$1.50High
3/26/2019Roth CapitalReiterated RatingBuy ➝ Neutral$1.70Medium
3/22/2019HC WainwrightDowngradeBuy ➝ Neutral$8.00 ➝ $1.50High
3/22/2019SunTrust BanksDowngradeBuy ➝ HoldHigh
3/11/2019HC WainwrightLower Price TargetBuy$14.00 ➝ $8.00High
2/13/2019Roth CapitalReiterated RatingBuyLow
12/6/2018SunTrust BanksLower Price TargetBuy$12.00High
12/6/2018Stifel NicolausDowngradeBuy ➝ Hold$4.00High
12/6/2018OppenheimerSet Price TargetBuy$14.00 ➝ $10.00High
11/5/2018HC WainwrightReiterated RatingBuyLow
10/1/2018OppenheimerSet Price TargetBuy$14.00High
8/2/2018OppenheimerSet Price TargetBuy$14.00Low
5/3/2018OppenheimerSet Price TargetBuy$14.00High
4/5/2018SunTrust BanksLower Price TargetBuy$4.30High
4/5/2018HC WainwrightLower Price TargetBuy ➝ Buy$17.00 ➝ $15.00High
4/5/2018OppenheimerSet Price TargetBuy$14.00High
3/22/2018OppenheimerReiterated RatingBuyLow
3/8/2018HC WainwrightReiterated RatingBuy$17.00High
3/7/2018OppenheimerSet Price TargetBuy$16.00High
3/1/2018OppenheimerInitiated CoverageBuy$16.00High
2/8/2018Roth CapitalInitiated CoverageBuy ➝ Buy$20.00High
1/24/2018S&P Equity ResearchBoost Price Target$5.02 ➝ $5.69High
11/2/2017HC WainwrightReiterated RatingBuy ➝ Buy$18.00 ➝ $17.00N/A
(Data available from 8/10/2017 forward)

News Sentiment Rating

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
1/12/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
2/11/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/13/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/12/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/12/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/11/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/11/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
8/10/2022

Current Sentiment

  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

  • No positive mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.
Conatus Pharmaceuticals logo
Conatus Pharmaceuticals Inc., a biotechnology company, focuses on the development and commercialization of novel medicines for the treatment of liver diseases in the United States. Its product candidate includes Emricasan, an orally active caspase protease inhibitor that is in Phase IIb clinical trials for post-orthotopic liver transplant as a result of hepatitis C virus infection with sustained viral response; for portal hypertension; for liver fibrosis caused by nonalcoholic steatohepatitis; and for liver function. The company is also developing CTS-2090, an orally active inhibitor of caspase 1, which is in preclinical development stage for treating chronic diseases involving inflammasome pathways. The company has a collaboration agreement with Novartis to conduct three Phase IIb clinical trials. Conatus Pharmaceuticals Inc. was founded in 2005 and is headquartered in San Diego, California.
Read More

Today's Range

Now: $2.26
Low: $2.21
High: $2.43

50 Day Range

MA: $1.00
Low: $0.56
High: $1.34

52 Week Range

Now: $2.26
Low: $0.23
High: $1.07

Volume

534,467 shs

Average Volume

1,283,592 shs

Market Capitalization

$74.96 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.84

Frequently Asked Questions

What sell-side analysts currently cover shares of Conatus Pharmaceuticals?

The following Wall Street sell-side analysts have issued stock ratings on Conatus Pharmaceuticals in the last year:
View the latest analyst ratings for CNAT.

What is the current price target for Conatus Pharmaceuticals?

0 Wall Street analysts have set twelve-month price targets for Conatus Pharmaceuticals in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for Conatus Pharmaceuticals in the next year.
View the latest price targets for CNAT.

What is the current consensus analyst rating for Conatus Pharmaceuticals?

Conatus Pharmaceuticals currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for CNAT.

What other companies compete with Conatus Pharmaceuticals?

Other companies that are similar to Conatus Pharmaceuticals include Annovis Bio, Bolt Biotherapeutics, Atreca, Pyxis Oncology and NuCana. Learn More about companies similar to Conatus Pharmaceuticals.

How do I contact Conatus Pharmaceuticals' investor relations team?

Conatus Pharmaceuticals' physical mailing address is 16745 W. Bernardo Dr. Suite 250, San Diego CA, 92127. The biotechnology company's listed phone number is 858-376-2600 and its investor relations email address is [email protected] The official website for Conatus Pharmaceuticals is www.conatuspharma.com. Learn More about contacing Conatus Pharmaceuticals investor relations.